Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

NCT05830084 | Active Not Recruiting Phase 1

• 3 other identifiers: 2022-002874-102023-503322-39-002022/3545
• Study Type: interventional
• Target: 23
• Locations: 6 countries
• Sites: 13

Brief Summary

New drug efficacy in ES has been disappointing in the last decades and no new drugs have been successfully introduced up to now in front line treatment. Among the tested drugs, early clinical data suggest that strategies using multi-targeted tyrosine kinase inhibitors (TKI) with anti-angiogenic activities are among the most efficient and may be beneficial in the treatment of patients with ES. Several TKI have been and are currently being tested as single-agent in patients with relapsed/refractory ES with encouraging results in phase II trials. Regorafenib has shown promising activity in Ewing sarcoma relapse setting, Nevertheless, regorafenib has never been combined with the intensive chemotherapy VDC/IE schedule and therefore this combination needs to be evaluated in order to avoid dose reduction of the current standard treatment and hence its efficacy. The current clinical trial has been therefore designed to test the feasibility of regorafenib with ES conventional chemotherapy. It consists of a phase Ib that will only recruit patients with multi-metastatic (other than lungs/pleura only) ES, that present the highest unmet medical need (2 year EFS: 33%, similar to patients with relapse/refractory ES).

Conditions

Ewing Sarcoma

Outcome Measures

Primary Outcomes (1)

• Occurrence of Dose-Limiting Toxicities (DLT)

  The dose-finding escalation will be driven by the occurrence of Dose-Limiting Toxicities (DLT), assessed over the first 28-day cycle (cycle 1), and defined as any of the following haematological and non-haematological events that occur during the DLT period (4 weeks after the start of treatment = cycle 1) and are at least possibly related (possibly, probably, or definitely) attributable to VDC/IE + regorafenib: * Any cardiac toxicity grade ≥ 3 * Any grade 3 or 4 (hematological or non-hematological) toxicity leading to delay of start of next course by \> 7 days (i.e: starting \> day 21). * Any dose interruption or reduction due to toxicity which results in administration of less than 80% of the planned dosage of regorafenib or 75% of the planned dosage of chemotherapy. * Any grade 3 or 4 toxicity resulting in discontinuation of the new combination * Any grade 5 toxicity related to study treatment (death)

  28 days after the start of treatment

Secondary Outcomes (2)

• Overall Survival (OS)

  Until 18 months after inclusion of the last patient

• Progression-Free Survival (PFS)

  Until 18 months after inclusion of the last patient

Study Arms (1)

Induction chemotherapy (VDC/IE) and local treatment /consolidation chemotherapy

EXPERIMENTAL

Standard ES treatment consists of: induction chemotherapy (VDC/IE) and local treatment (surgery/radiotherapy), followed by consolidation chemotherapy (VC/IE)/ Bu-Mel (according to physician and patient choice). Regorafenib will be administered during induction chemotherapy (VDC/IE) and during consolidation chemotherapy with conventional chemotherapy (VC/IE) but not Bu-Mel therapy Conventional chemotherapy will be administered at the recommended dose (100%) and only regorafenib will be escalated/de-escalated. Regorafenib will only be given concomitant to radiotherapy in case the primary tumor is located in the extremities. In case of primary tumors located in the pelvis, abdomen, thorax, spine, brain, head or neck, regorafenib will be stopped at least 1 week before start of radiotherapy.

Drug: regorafenib tablet

Interventions

regorafenib tablet DRUG

Regorafenib will be escalated/de-escalated, starting at DL0: * DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D) * DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D) * DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)

Induction chemotherapy (VDC/IE) and local treatment /consolidation chemotherapy

Eligibility Criteria

• Age: 2 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Any histologically and genetically confirmed Ewing sarcoma of bone or soft tissue, or round cell sarcomas which are 'Ewing's-like' but negative for EWSR1 gene rearrangement
• Metastatic disease
• Age ≥2 years and \<50 years (from second birthday to 49 years 364 days)
• Patient assessed as medically fit to receive the Ewing sarcoma standard multimodal treatment and regorafenib, including:
• Absolute Neutrophil Count (ANC) ≥ 0.75x10\^9/L, platelets ≥ 75x10\^9/L.
• Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 5×ULN
• Bilirubin ≤ 2×ULN
• Creatinine \< 2x ULN or creatinine clearance \>60 ml/min/1.73 m\^2
• International normalized ratio (INR)/ Partial thromboplastin time (PTT). INR and PTT ≤ 1.5 x ULN. INR \& PTT ≤ 1.5xULN
• Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) ≥50%) at baseline, as determined by echocardiography
• Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as: a BP \<95th percentile for sex, age, and height at screening (as per National Heart Lung and Blood Institute \[NHLBI\] guidelines) and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1. Patients \>18 years old should have BP ≤ 150/90 mmHg.
• No prior treatment for Ewing sarcoma other than surgery
• Negative pregnancy test for female patients of childbearing potential within 7 days prior to study registration.
• Patient agrees to use highly effective contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where applicable
• Subject must be able to swallow and retain oral medication.

You may not qualify if:

• Localized tumor or metastatic disease to lung/pleura only.
• Contra-indication to the Ewing sarcoma standard multimodal treatment
• Pregnant or breastfeeding women or intending to become pregnant during the study.
• Follow-up not possible due to social, geographic or psychological reasons
• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of oral drugs
• A clinically significant ECG abnormality, including a marked prolonged QTcF interval (eg, a repeated demonstration of a QTcF interval \>480 msec) Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality, unstable angina, active coronary artery disease and myocardial infarction within 6 months before randomization.) Uncontrolled hypertension (systolic pressure \>150 mmHg or diastolic pressure \> 90 mmHg on repeated measurement) despite optimal medical management
• Previous arterial or venous thromboembolisms Grade ≥ 3 per CTCAE v5.0
• Hypersensitivity to any active substance or to any excipients
• Radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation
• Major surgical procedure or significant traumatic injury within 28 days before starting study treatment
• Non-healing wound, ulcer or bone fracture.
• Uncontrolled systemic or local infection requiring systemic treatment
• Any anticoagulant therapy (risk of hemorrhage with Regorafenib)
• Interstitial lung disease with ongoing signs and symptoms.
• Known prior history of HBV, HCV, HIV

Sponsors & Collaborators

• Gustave Roussy, Cancer Campus, Grand Paris: lead
• Bayer: collaborator

Study Sites (13)

Queensland Children's Hospital

Brisbane, Australia

Location

Monash Children's Hospital

Clayton, Australia

Location

Royal Children's Hospital

Parkville, Australia

Location

Perth Children's Hospital

Perth, WA6009, Australia

Location

Rigshospitalet

Copenhagen, DK-2100, Denmark

Location

CHU Bordeaux

Bordeaux, France

Location

Centre Oscar Lambret

Lille, France

Location

centre Léon Bérard

Lyon, France

Location

Institut Curie

Paris, France

Location

Gustave Roussy

Villejuif, Île-de-France Region, 94805, France

Location

Istituto Nazionale dei Tumori

Milan, 20133, Italy

Location

Princess Máxima Center

Utrecht, 113, Netherlands

Location

Vall d'Hebron University Hospital

Barcelona, 119-12, Spain

Location

MeSH Terms

Conditions

Sarcoma, Ewing

Interventions

regorafenib

Condition Hierarchy (Ancestors)

Osteosarcoma; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Study Officials

• Pablo Berlanga, MD

  Gustave Roussy, Cancer Campus, Grand Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Patient with Ewing Sarcoma male or female age ≥2 years and \<50 years (from second birthday to 49 years 364 days) who are assessed as medically fit to receive the Ewing sarcoma standard multimodal treatment and regorafenib. Patients will benefit from the social security coverage in force in their country and will have received free and informed information allowing the collection of their consent.

Study Record Dates

• First Submitted: April 13, 2023
• First Posted: April 26, 2023
• Study Start: June 16, 2023
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: January 6, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

DK (1); ES (1); IT (1); NL (1); FR (5); AU (4)